Neurofibromatosis
2017 Neurofibromatosis Research Highlights
- Decreasing the Clinical Impact of Neurofibromatosis – New Clinical Trials Funded Through the Neurofibromatosis Research Program
- Deletion of Anaplastic Lymphoma Kinase improves cognitive impairments in a mouse model of Neurofibromatosis Type 1
- Study Finds that Lovastatin is Not Effective for Treating Learning or Attention Impairments in Children with NF1
- Opioid Receptor Signaling Crosstalk to Ras Protein is Mediated by Neurofibromin 1
Last updated Thursday, May 26, 2022